|View printer-friendly version|
|KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses|
This study was a randomized, single-blind, placebo-controlled, dose-ranging study that enrolled 53 horses (40 horses in three KIND-014 groups with different doses and dosing schedules, 13 horses in the placebo group). The objective was to determine the effective dose of KIND-014 for the treatment of gastric ulcers in horses. At Week 3, the gastric ulcer resolution (gastric ulcer score=0) rates in all three KIND-014 groups were statistically significantly higher than the placebo group (p-values < 0.05).
"We are very pleased with the positive results from this study and believe that KIND-014 has the potential to improve the treatment of horses with this important medical need. We look forward to advancing KIND-014 into the next phase of development," stated
About Kindred Biosciences
Russell Radefeld KindredBio
View original content with multimedia:http://www.prnewswire.com/news-releases/kindredbio-announces-positive-results-from-pilot-effectiveness-study-of-kind-014-for-the-treatment-of-gastric-ulcers-in-horses-300656157.html